AddedRisk Factors
•changes in trade policy applicable to the regions in which we do business, including changes in U.S. trade policies or the imposition of higher tariffs on products being shipped into and from the U.S.,
The 10-K against last year's
80 changes: 9 added, 19 removed, 52 reworded
10-K 0000031791-26-000012 (2026-02-24) vs 10-K 0000031791-25-000009 (2025-02-25)
The redline
The paragraph that changed most in each section
Marked against last year's 10-K:
cut words struck through, new words highlighted and underlined.
MD&A 306 words changed in this paragraph; it is 50% similar to last year's version.
Selling, general and administrative expenses for fiscal year 2024 2025 were $994.1 $991.9 million, as compared to $1,022.6 $994.1 million for fiscal year 2023, 2024, a decrease of $28.5 $2.2 million, or 3%. less than 1%. As a percentage of revenue, selling, general and administrative expenses decreased to 34.7% in fiscal year 2025 from 36.1% in fiscal year 2024 from 37.2% in fiscal year 2023. 2024. Amortization of intangible assets decreased and was $194.5 million for fiscal year 2025, as compared to $215.0 million for fiscal year 2024, as compared to $217.5 2024. Acquisition and divestiture-related expenses, which primarily consisted of legal and integration costs, were $3.8 million for fiscal year 2023. Restructuring and other costs, net, decreased and were $17.5 million for fiscal year 2024, as compared to $26.6 million for fiscal year 2023. 2025. Acquisition and divestiture-related expenses, which primarily consisted of legal and integration costs, and stock compensation expense related to the awards given to BioLegend employees post-acquisition, added an incremental expense of were $16.3 million for fiscal year 2024, as compared to $62.0 2024. Costs for significant environmental matters decreased expenses by $1.2 million for fiscal year 2023. 2025. Asset impairment was $22.8 million for fiscal year 2024. The above decreases were partially offset by an increase in restructuring and other costs, net, which was $55.9 million for fiscal year 2025, as compared to $17.5 million for fiscal year 2024. Restructuring and other costs, net in fiscal year 2025 primarily included charges associated with workforce reductions and facility consolidations in an effort to streamline operations, other exit costs, abandonments or associated asset write-downs, costs of terminating certain lease agreements or contracts, as well as costs associated with relocating facilities. In fiscal year 2025, severance actions associated with facility consolidations and cost reduction measures affected approximately 5% of our workforce. Significant litigation matters and settlements was $12.2 million for fiscal year 2025, as compared to $7.8 million for fiscal year 2024. Transformation costs were $9.3 million for fiscal year 2025. Purchase accounting adjustments decreased expenses by $0.5 million for fiscal year 2025, as compared to $1.7 million for fiscal year 2024, which primarily consisted of a change in fair value of contingent consideration, as compared to increasing expenses by $4.3 million for fiscal year 2023. Costs for significant environmental matters also added an incremental expense of $2.5 million for fiscal year 2023. The above decreases were partially offset by an increase in asset impairments, which added an incremental expense of $22.8 million for fiscal year 2024. Significant litigation matters and settlements added an incremental expense of $7.8 million for fiscal year 2024 and were minimal for fiscal year 2023. consideration. Excluding the factors items noted above, the net decrease in selling, general and administrative expenses was the result of increased slightly due to unfavorable changes in foreign exchange rates and investments in digital capabilities and innovation mostly offset by lower long-term incentive compensation costs, cost control and productivity initiatives and cost containment. initiatives.
Source: Item 7, 10-K 0000031791-26-000012 vs Item 7, 10-K 0000031791-25-000009
Accounting Policies 151 words changed in this paragraph; it is 34% similar to last year's version.
In November 2024, December 2025, the FASB issued Accounting Standards Update 2024-03, Disaggregation 2025-11, Interim Reporting (Topic 270): Narrow-Scope Improvements (“ASU 2025-11”), which clarifies the guidance in Topic 270 to improve the consistency of Income Statement Expenses (“ASU 2024-03”). interim financial reporting. ASU 2024-03 will require public 2025-11 provides a comprehensive list of required interim disclosures and introduces a disclosure principle requiring entities to disclose disaggregated information about specific natural expense categories underlying certain income statement expense line items. Such disclosures are required events since the end of the last annual reporting period that have a material impact on an annual and interim basis in a tabular presentation in the footnotes to the financial statements. In addition, entity. ASU 2024-03 requires public entities to disclose selling expenses on an annual and interim basis. The guidance 2025-11 is effective for annual periods beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. Early 2027, including interim periods within those fiscal years, with early adoption is permitted. The Company is in the process of determining currently evaluating the impact of this guidance on its financial statements and disclosures. adopting ASU 2025-11.
Source: Item 8, Note 1 – Nature of Operations and Accounting Policies, 10-K 0000031791-26-000012 vs Item 8, Note 1 – Nature of Operations and Accounting Policies, 10-K 0000031791-25-000009
Risk Factors 68 words changed in this paragraph; it is 69% similar to last year's version.
We are subject to data privacy and information security laws and regulations that apply to the collection, transmission, storage and use of personally identifying information, which among other things, impose certain requirements relating to the privacy, security and transmission of personal information, including comprehensive regulatory systems in the United States, European Union and the United Kingdom. The legislative and regulatory landscape for privacy and data protection continues to evolve in jurisdictions worldwide, and there has been an increasing focus on privacy and data protection issues with the potential to affect our business. Failure to comply with any of these laws or regulations could result in enforcement actions against us, including fines, claims for damages by affected individuals, damage to our reputation and loss of goodwill, any of which could have a material adverse effect on our business, financial condition, results of operations or prospects.
Source: Item 1A, 10-K 0000031791-26-000012 vs Item 1A, 10-K 0000031791-25-000009
Every change, by type
Sentences and paragraphs added, removed or reworded
Sentences and paragraphs of RVTY's Risk Factors and MD&A, 10-K 2026-02-24 against 10-K 2025-02-25. Each links to the text at sec.gov.
Quiet changes are sentences kept from last year with one to four words changed, at least one of them a hedge, a modal or a qualifier (may, could, will, not, significant, material…). A year or date rolling forward is not counted.
The full word list
adverse, adversely, all, although, anticipate, anticipates, any, approximately, believe, believes, can, cannot, certain, could, expect, expects, generally, however, if, intend, intends, largely, likely, many, material, materially, may, might, most, must, never, no, not, possible, primarily, probable, should, significant, significantly, some, substantial, substantially, unlikely, will, wouldAddedRisk Factors
Uncertainties related to the development, deployment and use of AI to advance our product offerings and improve internal operations may result in harm to our business and reputation.
AddedRisk Factors
We are advancing AI across our product and service offerings, and we are in the initial phases of expanding AI into the core functions of our business. The development and deployment of AI presents both risks and opportunities, and the implementation process could adversely impact the operations of our business as a whole. AI algorithms utilized in the deployment may be flawed or based on datasets that are biased or insufficient, and do not adequately take into account the underlying nature of our business. Failure to adequately train our employees during the deployment of AI could adversely impact our business or result in delays or errors in our offerings. Our competitiveness could also be negatively impacted by our failure to timely develop or deploy AI in our products and services, particularly if our competitors are successful in AI advancements in their products and services. The development of AI technology will require significant investment in resources and human capital and could increase our costs. There is uncertainty related to the legal and regulatory landscape surrounding rapidly evolving AI technologies, particularly in the areas of cybersecurity, intellectual property, and privacy and data protection. Failure to comply or appropriately respond to this developing landscape may result in increased legal liability, adverse regulatory action, or reputational damage.
AddedRisk Factors
We cannot predict the scope, timing, or impact of threatened U.S. tariffs on imports, the extent to which other countries may impose retaliatory trade restrictions, or the terms of future trade policy changes. Tariffs implemented during fiscal year 2025 increased our cost of revenue by approximately $25 million and reduced our gross margin by approximately $20 million, primarily affecting products manufactured in Europe for the U.S. market. While we have implemented mitigation strategies including manufacturing optimization, supplier collaboration, pricing adjustments, and temporary cost measures, these actions may not fully offset the impact of existing or future tariffs. Additional tariffs or trade restrictions may materially and adversely affect our results of operations, financial condition, and competitive position.
RemovedRisk Factors
RewordedRisk Factors
Our failure to comply with any of the restrictions in our new senior unsecured revolving credit facility, facility that we entered into in January 2025, the 2026 Notes, the 2028 Notes, the 2029 Notes, the March 2031 Notes, the September 2031 Notes, Notes and the 2051 Notes, including our new senior unsecured revolving credit facility that was entered into in January 2025, or any future indebtedness may result in an event of default under those debt instruments, which could permit acceleration of the debt under those debt instruments, and require us to prepay that debt before its scheduled due date under certain circumstances.
RewordedRisk Factors
Environmental events and political changes, including trade barriers and tariffs, such as the recent tariffs announced or imposed on U.S. trading partners and retaliatory measures threatened or imposed in response, and war or other conflicts, such as the current conflicts conflict in Ukraine and the Middle East, Ukraine, some of which may be disruptive, could interfere with our supply chain, our customers and all of our activities in a particular location.
RewordedRisk Factors
If we fail to accurately foresee our customers’ needs and future activities, we may invest heavily in research and development of products that do not lead to significant revenue.
Show the other 31
RewordedRisk Factors
In addition, global health crises or pandemics, changes in trade policy, actual or threatened tariffs, wars, conflicts, or other changes in a country’s or region’s political or economic conditions, could have a significant adverse effect on our supply chain.
RewordedRisk Factors
Adverse changes in our business, adverse changes in the key valuation assumptions used to determine the fair value of our reporting units, or the failure to grow our Life Sciences and Diagnostics segments may segments, could result in an impairment of our intangible assets, which could adversely affect our results of operations.
AddedMD&A
post-acquisition added an incremental expense of $0.6 million for fiscal year 2024. Amortization of intangible assets was $141.1 million for fiscal year 2025, as compared to $144.4 million for fiscal year 2024.
AddedMD&A
Tariffs enacted and implemented during fiscal year 2025 increased our cost of revenue by approximately $25 million. Through proactive mitigation efforts, the net impact on gross margin was approximately $20 million. The majority of this impact affected products manufactured in Europe and sold in the U.S. market. Our comprehensive mitigation strategy included manufacturing optimization, supplier collaboration, selective pricing adjustments, and targeted temporary cost measures to minimize ongoing financial exposure.
AddedMD&A
Our outstanding €500,000 Principal 1.875% Senior Unsecured Notes due in 2026 (“2026 Notes”) will mature in July 2026. We expect to repay the 2026 Notes with our existing cash on hand or borrowings under our senior unsecured revolving credit facility, or a combination thereof.
AddedMD&A
Income taxes: Significant judgment is required in determining our worldwide provision for income taxes and recording the related tax assets and liabilities. In the ordinary course of our business, there are operational decisions, transactions, facts and circumstances, and calculations for which the ultimate tax determination is not certain. Furthermore, our tax positions are periodically subject to challenge by taxing authorities throughout the world. We provide reserves for potential payments of tax to various tax authorities related to uncertain tax positions. These reserves are based on a determination of whether a tax benefit taken by the Company in its tax filings is more likely than not to be sustained upon audit based on its technical merits. The tax benefit recognized is measured as the largest amount that is more likely than not to be realized upon ultimate settlement. We regularly review our tax positions in each significant taxing jurisdiction and adjustments are made to our unrecognized tax benefits when: (i) facts and circumstances regarding a tax position change, causing a change in our judgment regarding that tax position; (ii) a tax position is effectively settled with a tax authority at a differing amount; and/or (iii) the statute of limitations expires regarding a tax position. Any significant impact as a result of changes in underlying facts, law, tax rates, tax audit, or review could lead to adjustments to one or more of our income tax expense, our effective tax rate, or our cash flow, see Note 6, Income Taxes, in the Notes to the Financial Statements.
AddedMD&A
Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of assets and liabilities and their respective tax bases. This method also requires the recognition of future tax benefits such as net operating loss carryforwards and tax credits, to the extent that realization of such benefits is more likely than not. We have established valuation allowances against a variety of deferred tax assets, including state net operating loss carryforwards, state income tax credit carryforwards, and certain foreign tax attributes. Valuation allowances take into consideration our ability to utilize these deferred tax assets and reduce the value of such items to the amount that is deemed more likely than not to be recoverable. In evaluating our ability to recover our deferred tax assets within the jurisdiction from which they arise, we consider all available positive and negative evidence, including reversals of deferred tax liabilities, projected future taxable income, tax planning strategies, and results of recent operations. In projecting future taxable income, we begin with historical results adjusted for non-recurring income and expense and incorporate assumptions and judgments about the future pretax operating income adjusted for items that do not have tax consequences. These assumptions about future taxable income require significant judgment and are consistent with the plans and estimates we are using to manage the underlying business. Changes in our assumptions regarding the appropriate amount for valuation allowances could result in an increase or decrease in the valuation allowance, with a corresponding charge or benefit to our tax provision.
RemovedMD&A
RemovedMD&A
RemovedMD&A
RemovedMD&A
RemovedMD&A
RemovedMD&A
RemovedMD&A
RemovedMD&A
RemovedMD&A
RemovedMD&A
RemovedMD&A
RemovedMD&A
RewordedMD&A
As a percentage of revenue, cost of revenue increased to 45.2% in fiscal year 2025 from 44.2% in fiscal year 2024 from 44.0% in fiscal year 2023, 2024, resulting in a decrease in gross margin of approximately 16 104 basis points to 54.8% in fiscal year 2025 from 55.8% in fiscal year 2024 from 56.0% 2024, primarily due to increased tariffs, unfavorable changes in foreign exchange rates and product mix shift, partially offset by the completion of product rebranding efforts in fiscal year 2023 due to an unfavorable shift in product mix and higher product costs, partially offset by pricing actions and productivity initiatives. 2024.
RewordedMD&A
The variation in our effective tax rate from the statutory rate for fiscal year 2024 2025 was primarily the result of general business impacted by federal tax credits of $17.6 million, a prior year true-up related to the tax on foreign earnings of approximately $9.4 $24.0 million, and favorability in our the net benefits of U.S. taxation international tax regimes of multinational operations of $28.9 $6.6 million, which were partially offset by an increase in valuation allowance $2.7 million of $29.8 million. other items.
RewordedMD&A
RewordedMD&A
RewordedMD&A
Segment operating margin decreased 214 139 basis points to 32.0% in fiscal year 2025, as compared to 33.4% in fiscal year 2024, as compared to fiscal year 2023, primarily due to lower unfavorable changes in volume leverage and continued foreign exchange rates, product mix shifts and investments in new product development, development and digital capabilities and growth initiatives, partially offset by pricing actions and productivity initiatives. capabilities.
RewordedMD&A
Our consolidated gross margin decreased 16 104 basis points in fiscal year 2024, 2025, as compared to fiscal year 2023, 2024, primarily due to an increased tariffs, unfavorable shift changes in foreign exchange rates, and product mix and higher product costs, shift, partially offset by pricing actions and productivity initiatives. the completion of product rebranding efforts in fiscal year 2024.
RewordedMD&A
Improvements to Reportable Segment Income Tax Disclosures (“ASU 2023-07”) 2023-09”) during fiscal year 2024 2025 and have included applied the additional disclosures related to the reportable segments guidance on a prospective basis, as disclosed in Note 21, Industry Segment and Geographic Area Information, 6, Income Taxes, in the Notes to Consolidated Financial Statements.
RewordedMD&A
Acquisition and divestiture-related expenses, which primarily consisted of legal and integration costs, and stock compensation expense related to the awards given to BioLegend employees post-acquisition, added an incremental expense of $16.3 were $3.8 million for fiscal year 2024, as compared to $62.0 million for fiscal year 2023. 2025.
RewordedMD&A
The increase in our Diagnostics Life Sciences segment revenue during fiscal year 2024 was due to driven by an increase of $43.7 $35.6 million in immunodiagnostics revenue and an increase of $22.6 million in reproductive health Software revenue, partially offset by a decrease of $23.7 $3.1 million in applied genomics Life Sciences Solutions revenue.
RewordedMD&A
RewordedMD&A
The cash provided by operating activities for fiscal year 2024 2025 was principally a result of income from continuing operations of $283.1 $239.9 million, adjustments for non-cash charges aggregating to $400.2 $445.9 million, including depreciation and amortization of $427.8 $405.3 million, and a net cash decrease from changes in working capital of $18.3 million. $96.8 million, primarily due to timing of collections in China during fiscal year 2025.
RewordedMD&A
The above decreases were partially offset by an increase in asset impairments, restructuring and other costs, net, which added an incremental expense of $22.8 was $55.9 million for fiscal year 2025, as compared to $17.5 million for fiscal year 2024.